The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model

Department of Human Oncology, University of Wisconsin, Madison, WI 53792, USA.
Cancer Immunology and Immunotherapy (Impact Factor: 3.94). 02/2011; 60(5):731-8. DOI: 10.1007/s00262-011-0971-0
Source: PubMed


We investigated the anti-tumor effect of peritumoral resveratrol in combination with immunotherapy in vivo in neuroblastoma-bearing mice. Subcutaneous NXS2 tumors were induced in A/J mice. On day 10, some mice received 15 mcg of intravenous immunocytokine for 5 days, mice received 20 mg of peritumoral resveratrol twice a week (starting on day 12) for a total of 5 injections, and a separate group received a combination of both regimens. Tumor progression and survival were assessed every 3-4 days. Blood and primary tumor tissue samples were collected on day 20 for Complete Blood Count and CD45 immunohistochemistry and histology, respectively. The primary tumor regressed in all mice receiving peritumoral resveratrol. Most of these mice receiving peritumoral resveratrol alone developed metastatic tumors and recurrence of the primary tumor after cessation of therapy. When resveratrol and immunocytokine regimens were combined, 61% of the mice receiving this combination therapy resolved their primary tumors and survived without developing metastatic tumors, compared to 15 and 13% receiving resveratrol or immunocytokine alone, respectively. None of the therapeutic regimes prevented lymphocyte infiltration or affected the complete blood count. Greater necrosis was observed microscopically in tumors from mice receiving the combination therapy. These results demonstrate that the combination therapy of peritumoral resveratrol plus intravenous immunocytokine provides better anti-tumor effects in this model than either therapy alone.

Download full-text


Available from: Richard Yang, Oct 03, 2015
37 Reads
  • Source
    • "Resveratrol has generated a great enthusiasm in the research community as well as in the public due to its presumed health benefits, including the prevention of cancer [18], [19]. Its lack of potency combined with poor bioavailability limits its use as a drug as a single agent [20], but in absence of toxicity in humans, resveratrol constitutes an excellent candidate for adjuvant therapy [21], especially for the treatment of retinoblastoma [10], [16]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: For many cancers, the lack of potency and the toxicity of current drugs limits the dose achievable in patients and the efficacy of treatment. Among them, retinoblastoma is a rare cancer of the eye for which better chemotherapeutic options are needed. Combination therapy is a compelling approach to enhance the efficacy of current treatment, however clinical trials to test rationally designed combinations of approved drugs are slow and expensive, and limited by our lack of in-depth knowledge of drug specificity. Since many patients already turn to nutraceuticals in hopes of improving their condition, we hypothesized that certain approved drugs could potentially synergize with widely consumed supplements. Following this hypothesis, we devised an alternative screening strategy aimed at taking advantage of a bait compound such as a nutraceutical with potential therapeutic benefits but low potency, by screening chemical libraries for approved drugs that synergize with this companion effector. As a proof of concept, we sought to identify approved drugs with synergetic therapeutic effects toward retinoblastoma cells in combination with the antioxidant resveratrol, popular as a supplement. We systematically tested FDA-approved drugs and known bioactives seeking to identify such pairs, which led to uncovering only a few additive combinations; but to our surprise, we identified a class of anticancer drugs widely used in the clinic whose therapeutic effect is antagonized with resveratrol. Our observations could explain in part why some patients do not respond well to treatment. Our results validate this alternative approach, and we expect that our companion effector strategy could significantly impact both drug discovery and the nutraceutical industry.
    PLoS ONE 03/2013; 8(3):e59156. DOI:10.1371/journal.pone.0059156 · 3.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Minimum energy paths and energy barriers are calculated for the free data layer in elliptical magnetic random access memory elements using a recently developed method that combines the nudged elastic band method with finite-element micro-magnetics. The method calculates the magnetic states along the most probable reversal paths for applied fields below the zero temperature switching field. The reversal mode in the minimum energy path depends on the strength of the external field. With increasing easy axis field, the reversal mode becomes more inhomogeneous than at lower fields.
    IEEE Transactions on Magnetics 10/2003; 39(5-39):2839 - 2841. DOI:10.1109/TMAG.2003.816239 · 1.39 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Resveratrol, a nontoxic polyphenol, has been shown to inhibit tumor growth in a xenograft mouse model of neuroblasoma. However, resveratrol is rapidly metabolized, mainly to its glucuronidated and sulfated derivatives. This study demonstrates that resveratrol alone, and not the glucuronidated or sulfated metabolites, is taken up into tumor cells, induces a rise in [Ca(2+)](i), and ultimately leads to a decrease in tumor cell viability. A new water-soluble resveratrol formulation was delivered directly at the site of the tumor in a neuroblastoma mouse model. The amount of unmodified resveratrol associated with the tumor increased more than 1000-fold. The increase of unmodified resveratrol associated with the tumor resulted in tumor regression. The number of residual tumor cells that remained viable also decreased as the ratio of the metabolites relative to unmodified resveratrol declined.
    Journal of Agricultural and Food Chemistry 03/2011; 59(9):4979-86. DOI:10.1021/jf104901g · 2.91 Impact Factor
Show more